Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28995085 | 1.00 | MEN1 (0.60) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL1580771 | 0.85 | LMNA (0.53) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL30927863 | 0.85 | LMNA (0.53) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL1580767 | 0.85 | LMNA (0.53) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL24575927 | 0.85 | EPHX2 (0.64) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL7263715 | 0.83 | LMNA (0.61) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL6514206 | 0.83 | LMNA (0.61) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL8518963 | 0.83 | LMNA (0.61) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL6529748 | 0.83 | LMNA (0.61) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL29609692 | 0.83 | LMNA (0.61) | MEN1KMT2ALMNAGAASSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269834-A1 | COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269834-A1 | COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010022355-A1 | COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES | PURDUE RESEARCH FOUNDATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269834-A1 | COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES | SARS1, ACE2, ACE | MEN1 4233/4885KMT2A 3537/4885LMNA 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.